P. Moreillon, J.M. Entenza  Clinical Microbiology and Infection 

Slides:



Advertisements
Similar presentations
Targeting Multidrug-resistant Staphylococci with an anti-rpoA Peptide Nucleic Acid Conjugated to the HIV-1 TAT Cell Penetrating Peptide  Mostafa FN Abushahba,
Advertisements

Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times  F.B. Spencker, L. Staber, T. Lietz,
Gram-positive infections: lessons learnt and novel solutions
New epidemiology of Staphylococcus aureus infection in Asia
In-vitro interaction of azithromycin and fluoroquinolones against gram-positive and gram-negative bacteria  Matthew W. Ruble, Deborah H. Gilbert, Stephen.
G. Cornaglia, A. Lönnroth, M. Struelens 
M.F.Q. Kluytmans-VandenBergh, J.A.J.W. Kluytmans 
Approach to diagnosis of infective endocarditis
Molecular characterization of methicillin-resistant Staphylococcus aureus isolated over a 2-year period in a Qatari hospital from multinational patients 
Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and.
Shahin Nozohoor, Jan-Ingmar Flock, Anders Heimdahl 
The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria  M.J. Rybak  Clinical Microbiology and Infection 
Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive Spectrum  Ronald N. Jones, M.D., Mary.
Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae  M. Ballestero-Téllez,
E. Lindberg, I. Adlerberth, A.E. Wold 
Clinical impact of antibiotic-resistant Gram-positive pathogens
Quinolone resistance among Shigella spp
Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992–98  J. Robert, E. Cambau, K. Grenet, D.
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
J.-P. Stahl  Clinical Microbiology and Infection 
Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli  R.A. Hickman, D. Hughes,
P. Davey, C. Pagliari, A. Hayes  Clinical Microbiology and Infection 
Clinical Microbiology and Infection
Treatment of staphylococcal infections with cyclic lipopeptides
W. Witte, B. Pasemann, C. Cuny  Clinical Microbiology and Infection 
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and.
Enhanced antimicrobial activity of peptide-cocktails against common bacterial contaminants of ex vivo stored platelets  K.V.K. Mohan, S. Sainath Rao,
Inga Odenholt, Elisabeth Löwdin, Otto Cars 
Spa typing directly from a mecA, spa and pvl multiplex PCR assay—a cost-effective improvement for methicillin-resistant Staphylococcus aureus surveillance 
The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model  Matthew O'Brien, Thuy Quach,
Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci.
G. Höffken  Clinical Microbiology and Infection 
E.C. Böttger  Clinical Microbiology and Infection 
Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals  C. Nonhoff, O. Denis,
Bacterial resistance—the clinical challenge
M.R. Jacobs  Clinical Microbiology and Infection 
In vitro selection of antibiotic resistance in Pseudomonas aeruginosa
Levofloxacin in the treatment of ventilator-associated pneumonia
Isolation rate, T-serotyping and susceptibility to antibiotics of Group A Streptococcus from pediatric infections in Athens*   M. Kanellopoulou, A. Makri,
M. Aires-de-Sousa  Clinical Microbiology and Infection 
Clinical profile of ceftobiprole, a novel β-lactam antibiotic
Recent developments in staphylococcal scalded skin syndrome
J. Garau  Clinical Microbiology and Infection 
Single- and multistep selection study of the antipneumococcal activity of BMS compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin 
Y. Tveten, A. Jenkins, A.G. Allum, B.-E. Kristiansen 
Can β-lactams be re-engineered to beat MRSA?
Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals  G.L. Cartolano,
A.W. Karchmer  Clinical Microbiology and Infection 
P.M. Hawkey  Clinical Microbiology and Infection 
Use of broth enrichment and real-time PCR to exclude the presence of methicillin- resistant Staphylococcus aureus in clinical samples: a sensitive screening.
Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock.
Effect of antibiotics, alone and in combination, on Panton–Valentine leukocidin production by a Staphylococcus aureus reference strain  O. Dumitrescu,
Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals  M.E. Reverdy, S. Jarraud, S. Bohin-Duhreux, E.
G.M. Rossolini, E. Mantengoli  Clinical Microbiology and Infection 
M.B. Kerrn, N. Frimodt-Møller, F. Espersen 
Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin  G. Drusano  Clinical Microbiology and Infection 
P. Kaltsas, S. Want, J. Cohen  Clinical Microbiology and Infection 
Can pharmacokinetic–pharmacodynamic parameters provide dosing regimens that are less vulnerable to resistance?  P. Courvalin  Clinical Microbiology and.
Overview of cefixime use in community-acquired infections
Active surveillance of antibiotic resistance prevalence in urinary tract and skin infections in the outpatient setting  A. Kronenberg, S. Koenig, S. Droz,
Abstracts Clinical Microbiology and Infection
New oral cephalosporins in pediatric community-acquired infections
J. Wilson, S. Elgohari, D. M. Livermore, B. Cookson, A. Johnson, T
In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: a 24-country study  R. Goering, C.-E. Nord, R.
A. Manzur, F. Gudiol  Clinical Microbiology and Infection 
B.A. Cunha  Clinical Microbiology and Infection 
Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group†   H. Goossens  Clinical.
G.C. Schito  Clinical Microbiology and Infection 
Joshua P. Metlay, Daniel E. Singer  Clinical Microbiology and Infection 
Presentation transcript:

Antibiotic resistance: learning from animal feeds and animal experimentation  P. Moreillon, J.M. Entenza  Clinical Microbiology and Infection  Volume 7, Pages 13-18 (January 2001) DOI: 10.1046/j.1469-0691.2001.00068.x Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Outcome of 3-day treatment of experimental endocarditis due to strain MRSA P8 with either levofloxacin (equivalent to 500 mg of oral levofloxacin once a day in humans) or ciprofloxacin (equivalent to 750 mg of oral ciprofloxacin twice a day in humans). Each dot in the figure represents the bacterial density in the vegetation of a single animal. Control animals were killed at the start of therapy, i.e. 12 h after inoculation. Treated rats were killed 12 h after the trough serum level of the last antibiotic dose. The two open dots in the ciprofloxacin treatment group represent two animals in which bacteria with increased (eight times) MICs of ciprofloxacin were isolated from the valve. P < 0.05 indicates statistically significant differences between the incidence of valve infection, determined by the Fisher's exact test. Clinical Microbiology and Infection 2001 7, 13-18DOI: (10.1046/j.1469-0691.2001.00068.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Selection of levofloxacin (LEVO)- and ciprofloxacin (CIPRO)-resistant derivatives by exposure of a methicillin-susceptible (MSSA 112, left panel) and a methicillin-resistant (MRSA P8, right panel) strain of S. aureus to stepwise increasing concentrations of antibiotics. Series of tubes containing 2-fold serial dilutions of either test drug were inoculated with a final concentration of 105 CFU/mL of the test organisms and further incubated for 24 h at 35°C, as for MIC tests. On the next day, the tube with the highest antibiotic concentration still showing turbidity was used to inoculate a new series of antibiotic-containing tubes. The procedure was repeated and the increase in MIC was followed over time. Both quinolones selected for derivatives with progressive increase in their MICs. However, resistance developed more slowly with levofloxacin than with ciprofloxacin. Clinical Microbiology and Infection 2001 7, 13-18DOI: (10.1046/j.1469-0691.2001.00068.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Population analysis profile of the ciprofloxacin-resistant laboratory mutant P8/128 (closed squares) and a ciprofloxacin-resistant clinical isolate of S. aureus (closed triangles) grown on agar plates containing increasing concentrations of Y-688. Large bacterial numbers (up to 1010 CFUs) were spread on plates containing 2-fold-increasing concentrations of the drug. Resistant variants able to grow in the presence of increased concentrations of Y-688 were counted after 48 h of incubation at 35°C. Clinical Microbiology and Infection 2001 7, 13-18DOI: (10.1046/j.1469-0691.2001.00068.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions